(Q28186482)

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

The role of presenilins in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Results of a high-resolution genome screen of 437 Alzheimer's disease families

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Translating cell biology into therapeutic advances in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Alzheimer's disease: genetic studies and transgenic models

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain.

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Apolipoprotein E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoform-specific manner

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

A protective role of the low density lipoprotein receptor-related protein against amyloid beta-protein toxicity

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells.

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Apolipoprotein E receptors: linking brain development and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Role of apoe/Abeta interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

The use of measured genotype information in the analysis of quantitative phenotypes in man. II. The role of the apolipoprotein E polymorphism in determining levels, variability, and covariability of cholesterol, betalipoprotein, and triglycerides in

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Effects of apolipoprotein E genotype on blood lipid composition and membrane platelet fluidity in Alzheimer’s disease

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Plasma lipids and cholesterol esterification in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Cholesterol accumulates in senile plaques of Alzheimer disease patients and in transgenic APP(SW) mice

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Statins and the risk of dementia

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Mechanisms of neurodegenerative disorders: Part 1: protein aggregates.

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Serum lipoprotein levels, statin use, and cognitive function in older women

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people.

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Fluvastatin: effects beyond cholesterol lowering

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

The Alzheimer amyloid precursor is associated with the detergent- insoluble cytoskeleton

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

A detergent-insoluble membrane compartment contains A beta in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

The interaction between Alzheimer amyloid beta(1-40) peptide and ganglioside GM1-containing membranes

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Amyloid beta-protein (A beta) associated with lipid molecules: immunoreactivity distinct from that of soluble A beta.

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

The role of cholesterol in the biosynthesis of beta-amyloid

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Secretory processing of amyloid precursor protein is inhibited by increase in cellular cholesterol content

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10.

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells.

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Induction of the cholesterol transporter ABCA1 in central nervous system cells by liver X receptor agonists increases secreted Abeta levels

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Roles of acyl-coenzyme A:cholesterol acyltransferase-1 and -2

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

The neurodegeneration mutant löchrig interferes with cholesterol homeostasis and Appl processing

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Cholesterol metabolism in the brain

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1.

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer disease?

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

The metabolism of cholestanol, cholesterol, and bile acids in cerebrotendinous xanthomatosis

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021

Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1038%2FNN0403-345

7 January 2021